Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric antigen receptor T-cell (CAR T-cell) therapy through the Cancer Drugs Fund.
Tisagenlecleucel, also known as Kymriah and made by Novartis, is recommended for adults with relapsed or refractory diffuse large B-cell lymphoma.
It will be offered to people whose disease has not responded or those whose disease has relapsed after treatment with two or more courses of chemotherapy.
